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ABSTRACT
Introduction: The improvement in breast cancer
survival rates, along with the expected overdiagnosis
and overtreatment associated with breast cancer
screening, requires a comprehensive assessment of its
burden. Neurological complications can have a
devastating impact on these patients; neuropathic pain
and chemotherapy-induced peripheral neuropathy are
among the most frequently reported. This project aims
to understand the burden of neurological complications
of breast cancer treatment in Northern Portugal, and
their role as mediator of the impact of the treatment in
different dimensions of the patients’ quality of life.
Methods and analysis: A prospective cohort study
was designed to include 500 patients with breast
cancer, to be followed for 3 years. The patients were
recruited at the Portuguese Oncology Institute of Porto
and evaluations were planned at different stages:
pretreatment, after surgery, after chemotherapy
(whenever applicable) and at 1 and 3 years after
enrolment. Patients diagnosed with neuropathic pain or
chemotherapy-induced peripheral neuropathy
(subcohorts), were also evaluated at the moment of
confirmation of clinical diagnosis of the neurological
complication and 6 months later. In each of the follow-
up periods, a neurological examination has been
performed by a neurologist. Data were collected on
sociodemographic and clinical characteristics, quality
of life, sleep quality, and anxiety and depression.
Between January and December 2012, we recruited
and conducted the baseline evaluation of 506
participants. The end of the follow-up period is
scheduled for December 2015.
Ethics and dissemination: The study protocol was
approved by the Ethics Committee of the Portuguese
Oncology Institute of Porto and all patients provided
written informed consent. All study procedures were
developed in order to assure data protection and
confidentiality. Results from this project will be
disseminated in international peer-reviewed journals
and presented in relevant conferences.
INTRODUCTION
Breast cancer is the most frequent form of
cancer and an important cause of cancer
death among women, with an estimated 1.7
million new cases and half a million deaths
worldwide.1 Despite upward trends in inci-
dence rates, due to an increasing exposure
to risk factors and widespread use of mam-
mography screening,2 mortality has been
declining in most affluent settings,3 reflect-
ing improvements in access to earlier diagno-
sis and effective treatments.4 5 In Northern
Portugal, the number of cases is expected to
be nearly 50% higher in 2020,6 assuming the
most recent trends remain, and mortality
rates have been declining since the 1990s in
several regions.7
The improvement in breast cancer survival,8
along with the expected overdiagnosis and
overtreatment associated with breast cancer
screening,9 requires a comprehensive assess-
ment of the burden of cancer, accounting for
disability and losses in quality of life (QoL)
due to the disease, treatment and sequelae.10
Although health-related QoL in women with
breast cancer has been addressed in several
studies,11–13 little attention has been dedicated
to understanding the role of specific physical
and psychological adverse effects of cancer
management14–17 in different dimensions of
the patients’ QoL.
Strengths and limitations of this study
▪ This protocol describes an ongoing prospective
cohort study with baseline evaluation already
performed.
▪ The study was approved by the ethics committee
of the hospital where the patients were recruited.
▪ The results of this study will be submitted for
publication in international peer-reviewed
journals.
▪ The expected results may contribute to a better
understanding of the burden of neurological
complications of breast cancer treatment and
their role as mediators of the impact of the treat-
ment in different dimensions of the patients’
quality of life.
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Neurological complications of breast cancer treat-
ment, including cognitive impairment, chemotherapy-
induced peripheral neuropathy (CIPN), neuropathic
pain (NP), encephalopathy and stroke,18 19 may cause
symptoms more disabling than the cancer itself18; CIPN
and NP are among the most frequently reported.18 20 21
CIPN is a dose-limiting side effect of many chemother-
apeutic agents that may lead to dose reduction and/or
discontinuation of treatment.22 The incidence of CIPN
depends on chemotherapy regimens,22 but the role of
conditions such as diabetes or alcohol consumption
have seldom been addressed.23–25 Chronic NP is esti-
mated to affect over a third of treated patients,20 21 espe-
cially younger ones.26–29 Despite some studies addressing
the relationship between quality of sleep,30 31 anxiety
and depression32 and the occurrence of pain, there is
little information on the impact of these factors, specific-
ally in NP. Moreover, data on type of surgery26 29 and
radiotherapy28 29 33 as risk factors for NP are conflicting.
Although QoL is known to be impaired by pain,34 35
to our knowledge no previous studies addressed the role
of NP or CIPN as mediators of the effect of breast
cancer treatment in different dimensions of QoL.
The burden of neurological complications in women
with breast cancer, including NP and CIPN, remains
poorly understood, namely regarding their aetiology, fre-
quency and impact on patients’ QoL. Prospective studies
providing a comprehensive characterisation of these fre-
quent side effects, and a methodologically sound assess-
ment of their determinants and associations with
specific dimensions of QoL, may contribute to a more
accurate characterisation of the burden associated with
breast cancer in different settings, as well as help to
develop strategies to minimise the impact of these condi-
tions during treatment.
This project aims to understand the burden of neuro-
logical complications of breast cancer treatment and
their role as mediators of the impact of the treatment in
different dimensions of the patients’ QoL in Northern
Portugal. The main specific objectives are as follows:
1. To estimate the incidence of neurological complica-
tions during the first 3 years after the diagnosis of
breast cancer, and to characterise the clinical features
and management of NP and CIPN.
2. To quantify the relationship between factors such as
type of treatment, depression, anxiety and sleep dis-
turbance or diabetes and alcohol consumption and
the occurrence of NP and CIPN;
3. To assess the role of NP and CIPN as determinants of
the variation in different dimensions of the patients’
QoL.
METHODS AND ANALYSIS
Study design
This prospective cohort study was designed to evaluate a
cohort of 500 women with incident breast cancer (main
cohort) and subcohorts of patients diagnosed with NP
(NP subcohort) and CIPN (CIPN subcohort), during a
3-year follow-up period (figure 1).
The study comprises the evaluation of all participants
at baseline (before any treatment), 2 weeks after surgery,
3 weeks after chemotherapy (if applicable) and at 1 and
3 years after enrolment. In addition, the subcohorts of
patients are evaluated at the moment of confirmation of
clinical diagnosis of the neurological complication and
6-months after the diagnosis of the side effect (figure 1),
in order to evaluate the chronicity of such conditions.
The evaluations are performed by trained interviewers or
clinicians, as applicable.
Selection of participants
Women admitted to the Breast Clinic of the Portuguese
Institute of Oncology of Porto (IPO-Porto) suspected of
having an incident breast cancer were potentially eli-
gible. In 2012, we invited those who were proposed for
surgery, either as primary treatment or after neoadjuvant
therapy, aged 18 years or older, with histologically con-
firmed breast cancer diagnosed in the previous
3 months, not treated with chemotherapy and/or radio-
therapy for other primary cancer, not having received
any treatment for breast cancer before, not submitted to
a previous breast surgery and capable of understanding
the purposes of the study and willing to collaborate. We
excluded those expected to receive cancer treatments
other than surgery, if applicable, outside IPO-Porto.
We evaluated the cognitive function of each patient
who accepted the invitation to participate, using the
Montreal Cognitive Assessment.36 Those scoring less
than 17, or less than 16 for women over 65 years old,37
were excluded from further evaluation.
Study questionnaires
Table 1 depicts the questionnaires used to evaluate the
participants at baseline and at different stages of
follow-up, and table 2 describes the instruments validated
for the Portuguese population, which were used to assess
cognitive function,36 38 QoL,39–42 quality of sleep,43 44
anxiety and depression,45 46 NP,47 48 pain severity48 49 and
pain-related disability.48 50
Neurological evaluation
Newly occurring cases of neurological complications are
identified through referral by any member of the clin-
ical team, or during the systematic neurological evalua-
tions described in table 1. Prevalent cases identified at
the time of the scheduled evaluations are assigned an
estimated date of onset based on information provided
by the patients.
The systematic neurological evaluation, performed by
a neurologist, comprises the assessment of cognitive
functions, cranial nerves, muscular strength, sensitive
function, reflexes, Babinski signal and evaluation of gait
and coordination.
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Data analysis and sample size
We will compute cumulative incidence estimates and the
corresponding 95% CIs for each of the neurological com-
plications at 6, 12 and 36 months of follow-up. A sample
of about 500 participants is needed to estimate cumula-
tive incidences between 30 and 70% with a 95% CI up to
10% wide, or cumulative incidences near or under 30%
with a 95% CI up to 8% wide. We will conduct descriptive
analyses to characterise NP and CIPN regarding their
clinical features and management among the patients
included in the corresponding subcohorts.
To quantify the association between different factors
and the occurrence of NP and CIPN, we will compute
incidence rate ratios and 95% CI estimates, crude and
adjusted for sociodemographic, clinical and QoL vari-
ables, using Poisson regression. A sample of approxi-
mately 500 women was estimated to be necessary,
assuming a statistical power of 80%, a level of significance
of 5% and: (1) one-third of the sample exposed to each
of the risk factors evaluated (eg, mastectomy; anxiety
and/or depression; poor sleep quality), an incidence rate
of NP of at least 30/100 person-years in the first year and
a relative risk estimate of at least 1.5; and (2) approxi-
mately half of the women submitted to chemotherapy,
10% of the sample exposed to each of the risk factors
evaluated (eg, diabetes; high alcohol consumption), an
incidence rate of CIPN of at least 20/100 person-years in
the first year and a relative risk estimate of at least 2.
The association between NP and CIPN and the vari-
ation in QoL from baseline to 1-year evaluation and from
1-year to 3-year follow-up assessments will be quantified
through crude and adjusted incidence rate ratios and
95% CI estimates, using Poisson regression. A sample of
approximately 500 women was estimated to be necessary,
assuming a statistical power of 80%, a level of significance
of 5%, one-third of the sample with incident NP, an inci-
dence rate of 25/100 person-years for moderate clinically
meaningful worsening in QoL (decrease of at least 10
points in the Quality of Life Questionnaire of the
European Organization for Research and Treatment of
Cancer (QLQ-C30) score53) and a relative risk estimate
of at least 1.5. A sample of approximately 200 women was
estimated to be necessary, assuming a statistical power of
80%, a level of significance of 5%, one-fifth of the sample
with incident CIPN, an incidence rate of 25/100 person-
years for moderate clinically meaningful worsening in
QoL (decrease of at least 10 points in the QLQ-C30
score53) and a relative risk estimate of at least 2.
Training of the interviewers and use of standardised
procedures for data collection is expected to contribute
to a low proportion of missing data, and no imputation
is being planned.
We estimate that the 3-year evaluation will be accom-
plished for at least 90% of the participants, taking into
account the most recent survival data from Northern
Portugal54 and the fact that all women in our cohort were
submitted to surgical treatment. The evaluations will be
matched with routine appointments in the hospital, which
is expected to contribute to minimise further loss to
follow-up.
Figure 1 Study design and timing of baseline and follow-up evaluations in the main cohort and neuropathic pain and
chemotherapy-induced peripheral neuropathy subcohorts. CIPN, chemotherapy-induced peripheral neuropathy;
NP, neuropathic pain. *Not all patients are eligible for chemotherapy; †In addition to the evaluations that are performed for the
main cohort.
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Table 1 Description of methods used for evaluation of participants at baseline and at different stages of follow-up
Timing of evaluation
Methods used for evaluation of participants
Sociodemographic and
clinical characteristics
Neurological
evaluation MoCA HADS PSQI QLQ-BR23 QLQ-C30 BPI DN4 PDI
Main cohort of patients with breast cancer
Baseline ✓* ✓ ✓ ✓ ✓ ✓ ✓
Postsurgery ✓† ✓
Postchemotherapy ✓‡ ✓
1-year follow-up ✓§ ✓ ✓ ✓ ✓ ✓ ✓
3-year follow-up ✓¶ ✓ ✓ ✓ ✓ ✓ ✓ ✓** ✓** ✓**
Subcohort of patients diagnosed with NP††
Baseline ✓‡‡ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
6-month follow-up ✓‡‡ ✓ ✓ ✓ ✓ ✓ ✓** ✓** ✓**
Subcohort of patients diagnosed with
CIPN††
Baseline ✓§§ ✓ ✓ ✓
6-month follow-up ✓§§ ✓ ✓ ✓
*Data is collected on sociodemographic (birth date, address, marital status, education, occupation and alcohol consumption) and clinical (medication used, history of previous neurological
disease, diabetes, hypertension, thyroid pathology and oncological history) characteristics.
†Data is collected on type of surgery, cancer stage51 and proposed treatment after surgery.
‡Data is collected on chemotherapy (drugs used, duration of treatment and total dose).
§Data is collected on radiotherapy (irradiated areas, total dose and duration of treatment) and hormonotherapy (drug), and other data is updated (marital status, cancer stage51 and information
regarding chemotherapy and radiotherapy).
¶Data is collected on smoking habits, fruits and vegetables consumption, and physical activity. Marital status, alcohol consumption and information regarding cancer stage and treatment are
reviewed.
**Applicable only when NP is present at the moment of evaluation.
††In addition to the evaluations that are performed in the main cohort.
‡‡Data is collected concerning NP symptoms, aetiology, duration, localisation and pain management.
§§Data is collected regarding CIPN symptoms and chemotherapy details; CIPN is graded using Common Terminology Criteria for Adverse Events V.4.052 and Total Neuropathy score.24
BPI, Brief Pain Inventory48 49; CIPN, chemotherapy-induced peripheral neuropathy; DN4, Neuropathic Pain Questionnaire47 48; HADS, Hospital Anxiety and Depression Scale45 46; MoCA, The
Montreal Cognitive Assessment36 38; NP, neuropathic pain; PDI, Pain Disability Index48 50; PSQI, Pittsburgh Sleep Quality Index43 44; QLQ-BR23, Breast cancer-specific module of the Quality
of Life Questionnaire of the European Organization for Research and Treatment of Cancer39 40; QLQ-C30, Quality of Life Questionnaire of the European Organization for Research and
Treatment of Cancer.39 41
4
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Assembling of the main cohort and subcohorts and 1-year
follow-up
Figure 2 describes the assembling of the main cohort
and the NP and CIPN subcohorts. During 2012, all
patients admitted to the IPO-Porto with a potential diag-
nosis of breast cancer were evaluated (n=961) and those
who were proposed for surgical treatment and met the
eligibility criteria were invited to participate (n=588).
Table 2 Description of the instruments used for evaluation of the participants
Instruments Description Domains/subscales Score
MoCA36 38 Test for the rapid screening of
mild cognitive impairment—an
intermediate clinical state
between normal cognitive aging
and dementia
Attention and concentration;
executive functions; memory;
language; visuoconstructional skills;
calculations; orientation
Range: 0–30
Higher scores represent better
cognitive performance
HADS45 46 Scale with 14 questions
assessing anxiety and emotional
distress among patients during
the previous week
Depression; anxiety Range (for each subscale): 0–21
Scores greater than or equal to
11 represent a case of anxiety or
depression, as applicable
PSQI43 44 Index with 18 questions
assessing sleep quality and
disturbances during the previous
month.
Subjective sleep quality; sleep
latency; duration of sleep; habitual
sleep efficiency; sleep disorders; use
of medications for sleep; daytime
dysfunction
Range: 0–21
Scores greater than 5 indicate
poor sleep quality
QLQ-BR2339 40 Specific breast cancer scale with
23 questions assessing QoL in
patients with breast cancer
during the previous week and
month
Functional scales: body image;
sexual functioning; sexual
enjoyment; future perspective
Symptom scales/items: systemic
therapy side effects; breast
symptoms; arm symptoms; concern
about hair loss
Range (scales and single-item):
0–100
Higher scores for a functional
scale represent a healthy level of
functioning.
Higher scores for a symptom
scale/item represent a higher
level of symptomatology/
problems
QLQ-C3039 41 Scale with 30 questions
assessing QoL in patients with
cancer during the previous week
Global health status.
Functional scales: physical
functioning; role functioning;
emotional functioning; cognitive
functioning; social functioning.
Symptom scales/items: fatigue;
nausea and vomiting; pain;
dyspnoea; insomnia; appetite loss;
constipation; diarrhoea; financial
difficulties
Range (scales and single-item):
0–100
Higher scores for the global
health status and for a functional
scale represent a healthy level of
QoL and functioning,
respectively.
Higher scores for a symptom
scale/item represents a higher
level of symptomatology/
problems
BPI48 49 Questionnaire with 9 items used
to evaluate the severity of a
patient’s pain and the impact of
this pain on the patient’s daily
functioning in the past 24 h
Severity of pain; impact of pain on
daily function; location of pain; pain
medications; amount of pain relief in
the past 24 h or the past week
Range (for ‘severity of pain’ and
‘pain interference’): 0–10
Higher scores for ‘severity of
pain’ and ‘pain interference’
represent a higher level of pain
severity and pain interference,
respectively
DN447 48 Test with 4 questions (10 items)
for the screening of neuropathic
pain
Not applicable Range: 0–10
Scores greater than or equal to
4 are regarded as indicative of
neuropathic pain
PDI48 50 Index with 7 items designed to
assess pain-related disability,
providing information that
complements assessment of
physical impairment
Family/home responsibilities;
recreation; social activity; occupation;
sexual behaviour; self-care;
life-support activity
Range: 0–70
Higher scores represent greater
disability due to pain
BPI, Brief Pain Inventory; CIPN, chemotherapy-induced peripheral neuropathy; DN4, Neuropathic Pain Questionnaire; HADS, Hospital Anxiety
and Depression Scale; MOCA, The Montreal Cognitive Assessment; PDI, Pain Disability Index; PSQI, Pittsburgh Sleep Quality Index;
QLQ-BR23, Breast cancer-specific module of the Quality of Life Questionnaire of the European Organization for Research and Treatment of
Cancer; QLQ-C30, Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer; QoL, quality of life.
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Eighty patients with possible cognitive impairment were
excluded and two refused to participate (no reason for
refusing was specified). A total of 506 patients under-
went a baseline evaluation before the first proposed
treatment, constituting the main cohort. The subcohorts
of NP and CIPN patients included those with a diagnosis
of these conditions in the first year of follow-up.
The end of the follow-up period is scheduled for
December 2015.
ETHICS AND DISSEMINATION
Written informed consent was obtained from all partici-
pants after the aims and procedures of the investigation
had been fully explained by a member of the study group.
This is an observational investigation; as such we do
not anticipate the occurrence of harmful effects related
to participation in the study. To minimise the possible
discomfort due to the need to go to the hospital for
face-to-face evaluations or the duration of interviews,
data collection procedures were designed to last no
more than 60 min, and are scheduled to take place on
the same day as other appointments in the hospital as
part of regular clinical care.
All data regarding clinical aspects are collected by clin-
ical members of the research team and privacy is
assured. We guarantee data protection in accordance
with Portuguese law. Participants were coded with a
unique non-identifying number; the correspondence
between this code and the personal identifiable informa-
tion is stored in a file, to which only the principal investi-
gator can have access. Only the research team has access
to the database with anonymised data, saved on a
password-protected secure computer.
The expected results may contribute to a better under-
standing of the burden of neurological complications of
breast cancer treatment and their role as mediators of
the impact of the treatment in different dimensions of
the patients’ QoL. The main findings of the study will
be submitted for publication in international peer-
reviewed journals and proposed for presentation at rele-
vant international and national conferences. We will
issue press releases to promote the dissemination of
information relevant to the general population in the
mass media. Moreover, this study will also contribute to
the training of researchers through the production of
master and doctoral theses.
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Figure 2 Flow chart describing the assembling of the main cohort and the neuropathic pain and chemotherapy-induced
peripheral neuropathy subcohorts. CIPN, chemotherapy-induced peripheral neuropathy; CTX, chemotherapy; MoCA, The
Montreal Cognitive Assessment; NP, neuropathic pain; RT, radiotherapy; SPC, second primary cancer.
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